Venous Thromboembolism – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Venous Thromboembolism – Drugs In Development, 2024 report and make more profitable business decisions.
Venous thromboembolism (VTE) is a condition that occurs when a blood clot forms in a vein and blocks the blood flow. VTE can affect the deep veins of the legs or arms (deep vein thrombosis, or DVT) or the lungs (pulmonary embolism, or PE). VTE can cause serious complications such as tissue damage, organ failure, or death. VTE can be provoked by factors such as surgery, injury, infection, inflammation, or immobility. VTE can be prevented by using anticoagulant medications, compression stockings, or mechanical devices. VTE can be diagnosed by using tests such as ultrasound, computed tomography (CT) scan, or ventilation-perfusion (VQ) scan. VTE can be treated by using anticoagulant medications, thrombolytic medications, or surgical procedures.
The Venous Thromboembolism drugs in development market research report provide comprehensive information on the therapeutics under development for Venous Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Venous Thromboembolism and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Venous Thromboembolism | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 33 molecules, with 33 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Venous Thromboembolism therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Venous Thromboembolism pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Venous Thromboembolism treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acticor Biotech SASAlexion Pharmaceuticals Inc
Alfasigma SpA
Alphamab Oncology
Anthos Therapeutics Inc
Bayer AG
Bio-Synectics Inc
Bristol-Myers Squibb Co
CarboMimetics
China Resources Emde Biological Pharmaceutical Co Ltd
China Resources Pharmaceutical Group Ltd
CSPC Pharmaceutical Group Ltd
Guangzhou Recomgen Biotech Co Ltd
Indiana Lysis Technologies LLC
Jiangsu Hengrui Medicine Co Ltd
Jiangxi Jemincare Group Co Ltd
Kolmar Korea Co Ltd
Laboratorios Farmaceuticos Rovi SA
Lee's Pharmaceutical Holdings Ltd
Mudanjiang Youbo Pharmaceutical Co Ltd
Overseas Pharmaceuticals Ltd
Regeneron Pharmaceuticals Inc
Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
SupraGen LLC
Taho Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Techfields Pharma Co Ltd
Translational Sciences Inc
Verseon Corp
Zonhon Biopharma Institute Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Venous Thromboembolism reports